Table 1 Baseline demographic and laboratory characteristics of study participants in both phases
Variables | Pre-pharmacist directed-TDM phase (n = 100) | Post-pharmacist directed-TDM phase (n = 100) | p value |
|---|---|---|---|
Age | |||
Group-I: children of age 1–6 months | 22 (22.0%) | 19 (19.0%) | 0.895 |
Group-II: children of > 6 months–2 years | 14 (14.0%) | 16 (16.0%) | 0.887 |
Group-III: children of > 2–6 years | 47 (47.0%) | 51 (51.0%) | 0.765 |
Group-IV: children of > 6–12 years | 9 (9.0%) | 8 (8.0%) | 0.998 |
Group-V: children > 12–18 years | 8 (8.0%) | 6 (6.0%) | 0.958 |
Sex (male) | 61 (61.0%) | 59 (59.0%) | 0.988 |
Units of the hospital where VCM therapy initiated | |||
Emergency | 31 (31.0%) | 44 (44.0%) | 0.075 |
PICU | 11 (11.0%) | 10 (10.0%) | 0.899 |
Medicine | 21 (21.0%) | 18 (18.0%) | 0.682 |
NICU | 19 (19.0%) | 16 (16.0%) | 0.618 |
Surgery | 18 (18.0%) | 12 (12.0%) | 0.061 |
Indications of VCM use | |||
UTI | 9 (9%) | 7 (7.0%) | 0.895 |
Meningitis | 12 (12.0%) | 10 (10.0%) | 0.956 |
Endocarditis | 2 (2.0%) | 1 (1.0%) | 0.978 |
Skin and soft tissue infections | 8 (8.0%) | 10 (10.0%) | 0.959 |
Bacteraemia | 33 (33.0%) | 36 (36.0%) | 0.897 |
Pneumonia | 28 (28.0%) | 27 (27.0%) | 0.964 |
Osteomyelitis | 3 (3.0%) | 2 (2.0%) | 0.785 |
Intra-abdominal infections | 5 (5.0%) | 7 (7.0%) | 0.823 |
Baseline laboratory values at VCM initiation | |||
Creatinine clearance (ml/min)a | 72.5 (15.5–98.5) | 68.9 (10.8–97.2) | 0.391 |
While blood counts (× 109 Cells/L) | 10.2 (6.9–15.9) | 10.8 (7.1–16.0) | 0.699 |
Patients with impaired renal function | 19 (%) | 22 (%) | 0.119 |